VA-INTELSAT
7.11.2022 20:01:42 CET | Business Wire | Press release
Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks and leading provider of inflight connectivity (IFC), today announced that scale-up manufacturer SWISSto12 will produce the Intelsat 45 satellite (IS-45). With the order, Intelsat becomes the first commercial customer for the innovative HummingSat geostationary (GEO) telecommunications product.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221107005851/en/
Made with additive manufactured products, HummingSat complements much larger legacy spacecraft, boosting and expanding capacity where needed (Photo: Business Wire)
Scheduled for launch in 2025, Intelsat 45 will provide Ku-band fixed-satellite services enabling Intelsat to provide specialized and efficient service to Media and Network customers.
“The SWISSto12 product brings two innovations to meet our business needs,” said Jean-Luc Froeliger, SVP of Space Systems, Intelsat. “The small size addresses a gap in our fleet strategy, enabling us to be increasingly more targeted to meet specific customer requirements. In addition, the additive-manufacturing process used for this spacecraft is paving the way for faster satellite build cycles in the future. We are confident in the HummingSat technology and want to support the success of new players in the field of commercial communication satellites.”
HummingSats are just over one cubic meter in volume, one-tenth the size of conventional satellites placed in geostationary orbit. SWISSto12 is developing the satellites in collaboration with the European Space Agency (ESA) through its public-private-partnership program. Each HummingSat is designed to launch as a rideshare mission on a rocket carrying one or more large spacecraft to GEO transfer orbit. The new satellite product line recently passed its system requirements review, assessed by a panel of ESA experts.
Dr. Emile de Rijk, SWISSto12 founder and CEO: “The award of the IS-45 program by Intelsat is a landmark moment for SWISSto12. We are humbled to embark on this journey with Intelsat, who are the foundational architects of satellite communications. It is unprecedented for a specialist high growth scale-up to secure a contract of this depth with a leading telecommunications operator. It provides a solid start to our HummingSat product line to open a new chapter in the satellite communications industry.”
About Intelsat
As the foundational architects of satellite technology, Intelsat operates the world’s most trusted satellite telecom network. We apply our unparalleled expertise and global scale to connect people, businesses, and communities, no matter how difficult the challenge. Intelsat is building the future of global communications with the world’s first hybrid, multi-orbit, software-defined 5G network designed for simple, seamless, and secure coverage precisely when and where our customers most need it. Follow the leader in global connectivity and “Imagine Here,” with us, at Intelsat.com.
About Swissto12
SWISSto12 is a leading manufacturer of advanced satellite payloads and systems, including the HummingSat: a small yet powerful geostationary telecommunications satellite. The company’s satellites and payloads benefit from unique and patented 3D printing technologies and associated Radio Frequency (RF) product designs that deliver lightweight, compact, highly performing, and competitive RF functionality.
Besides its space portfolio, the company is also active in telecommunications, surveillance and radar applications for the aeronautic industry. SWISSto12 has developed commercially with success in Europe, the USA and Israel and is the fastest growing Swiss aerospace company. SWISSto12 spun off in 2011 from the Swiss Federal Institute of Technology in Lausanne (EPFL), is privately owned and backed by prominent Swiss and European Investors. Learn more about us: www.swissto12.com
Follow Us on Social Media:
Twitter | LinkedIn | Facebook | Instagram | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005851/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom